6o0m
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==crystal structure of BCL-2 F104L mutation with venetoclax== | |
| - | + | <StructureSection load='6o0m' size='340' side='right'caption='[[6o0m]], [[Resolution|resolution]] 1.75Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[6o0m]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6O0M OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6O0M FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=LBM:4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-cyclohexen-1-yl]methyl]piperazin-1-yl]-~{N}-[4-(oxan-4-ylmethylamino)-3-[oxidanyl(oxidanylidene)-$l^{4}-azanyl]phenyl]sulfonyl-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide'>LBM</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene></td></tr> | |
| - | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6o0m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6o0m OCA], [http://pdbe.org/6o0m PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6o0m RCSB], [http://www.ebi.ac.uk/pdbsum/6o0m PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6o0m ProSAT]</span></td></tr> |
| + | </table> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Birkinshaw, R W]] | ||
| + | [[Category: Colman, P M]] | ||
| + | [[Category: Czabotar, P E]] | ||
| + | [[Category: Luo, C S]] | ||
| + | [[Category: Apoptosis]] | ||
| + | [[Category: Bcl-2]] | ||
| + | [[Category: Complex]] | ||
| + | [[Category: Fda approved drug complex]] | ||
| + | [[Category: Protein-protein interface inhibitor]] | ||
| + | [[Category: Resistance mutation]] | ||
| + | [[Category: Venetoclax]] | ||
Revision as of 06:54, 23 May 2019
crystal structure of BCL-2 F104L mutation with venetoclax
| |||||||||||
